New Dopaminergic Antiparkinsonism Agents Findings from Hebrew University of Jerusalem Described (Rasagiline Exerts Neuroprotection towards Oxygen-Glucose-Deprivation/Reoxygenation-Induced GAPDH-Mediated Cell Death by Activating Akt/Nrf2...).

A recent study conducted by researchers at Hebrew University of Jerusalem has found that rasagiline, a selective monoamine oxidase B (MAO-B) inhibitor, has neuroprotective effects in the treatment of Parkinson's disease (PD). The study investigated the signaling pathways of rasagiline in neuronal cultures exposed to oxygen-glucose deprivation (OGD) and reoxygenation, and found that rasagiline provided neuroprotection by inhibiting cell death and increasing antioxidant enzymes through the Akt/Nrf2 redox-signaling pathway. These findings have potential implications for the development of neuroprotective drugs for PD and stroke therapy. [Extracted from the article]